Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.47 |
| ▸ | KDM1A | O60341 | 7/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13484227 | 1.00 | MAOA (0.47) | MAOAKDM1ACCR5MAOBCYP2C19 | |
| SCHEMBL684465 | 1.00 | MAOA (0.47) | MAOAKDM1ACCR5MAOBCYP2C19 | |
| SCHEMBL15084368 | 1.00 | MAOA (0.47) | MAOAKDM1ACCR5MAOBCYP2C19 | |
| SCHEMBL14330231 | 1.00 | MAOA (0.47) | MAOAKDM1ACCR5MAOBCYP2C19 | |
| SCHEMBL17948233 | 1.00 | MAOA (0.47) | MAOAKDM1ACCR5MAOBCYP2C19 | |
| SCHEMBL19341986 | 0.86 | KDM1A (0.50) | MAOAKDM1ACCR5MAOBADRA2A | |
| SCHEMBL19908542 | 0.86 | KDM1A (0.50) | MAOAKDM1ACCR5MAOBADRA2A | |
| SCHEMBL15084369 | 0.84 | KDM1A (0.37) | MAOAKDM1ACCR5HTR1ASLC6A2 | |
| SCHEMBL3870077 | 0.84 | MAOA (0.55) | MAOAKDM1ACCR5MAOBCYP2C19 | |
| SCHEMBL3870080 | 0.84 | MAOA (0.55) | MAOAKDM1ACCR5MAOBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9717730-B2 | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170157124-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9610289-B2 | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | GENENTECH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160228440-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160051550-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-9150549-B2 | Combinations of AKT inhibitor compounds and erlotinib, and methods of use | GENENTECH, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150548-B2 | Combinations of AKT inhibitor compounds and vemurafenib, and methods of use | GENENTECH, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140221386-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130065908-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8329701-B2 | Dihydrofuro pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110269773-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8003651-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157124-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | AKT1, AKT2, MTOR | MAOA 4476/4885KDM1A 3866/4885CCR5 1098/4885 |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | MAOA 3102/4885KDM1A 2382/4885CCR5 2114/4885 |
| US-20130065908-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, DTYMK, PIK3CA | MAOA 4329/4885KDM1A 2672/4885CCR5 1931/4885 |
| US-20160228440-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | AKT1, AKT2, MTOR | MAOA 4476/4885KDM1A 3866/4885CCR5 1098/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | MAOA 3650/4885KDM1A 1767/4885CCR5 1344/4885 |
| US-20110269773-A1 | DIHYDROFURO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DPYD, PIK3CA, DTYMK | MAOA 4219/4885KDM1A 2686/4885CCR5 1773/4885 |
| US-20160051550-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | AKT1, AKT2, MTOR | MAOA 4447/4885KDM1A 2947/4885CCR5 2157/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | MAOA 3650/4885KDM1A 1767/4885CCR5 1344/4885 |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | MAOA 3650/4885KDM1A 1767/4885CCR5 1344/4885 |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | MAOA 3650/4885KDM1A 1767/4885CCR5 1344/4885 |
| US-20140221386-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE | AKT1, AKT2, MTOR | MAOA 4532/4885KDM1A 3288/4885CCR5 2096/4885 |
| US-20110245230-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | MAOA 3742/4885KDM1A 2865/4885CCR5 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.